医学
医疗器械
临床试验
药品审批
重症监护医学
业务
作者
Eric Hsiao-Kuang Wu,Kevin Wu,Roxana Daneshjou,David Ouyang,Daniel E. Ho,James Zou
出处
期刊:Nature Medicine
[Springer Nature]
日期:2021-04-01
卷期号:27 (4): 582-584
被引量:214
标识
DOI:10.1038/s41591-021-01312-x
摘要
A comprehensive overview of medical AI devices approved by the US Food and Drug Administration sheds new light on limitations of the evaluation process that can mask vulnerabilities of devices when they are deployed on patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI